Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 ...

Dr Simon Cork, Senior Lecturer in Physiology, Anglia Ruskin University (ARU), said: ...